Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - buprenorphine hydrochloride - sublingual tablet - 2 milligram(s) - oripavine derivatives; buprenorphine

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - buprenorphine hydrochloride - sublingual tablet - 8 milligram(s) - oripavine derivatives; buprenorphine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ecuphar sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva santé animale sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

Canada - English - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Canada - English - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Canada - English - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

United States - English - NLM (National Library of Medicine)

avpak - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate  an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational st